Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Early Phase 1

Withdrawn

• Conditions: Advanced Solid Tumor; Metastatic Solid Tumor
• Interventions: Drug: MPT0B640

• Registration Number: NCT04294875
• Lead Sponsor: J Ints Bio

Brief Summary

Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with Locally Advanced or Metastatic Solid Malignancies

Phase I. Advanced or metastatic solid malignancy First in Human. HSP90 inhibitor Multi-center clinical trials. Open label.

To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640

Detailed Description

Classical 3+3 design to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640 .

Up to 9 times of administration, Oral suspension, once every 3rd day.

Study Timeline

• Study First Submitted: 2020-03-02
• Study First Submitted QC: 2020-03-02
• Study First Posted: 2020-03-04
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-04
• Last Update Posted: 2024-03-06
• Study Start: 2025-12
• Primary Completion: 2027-11
• Study Completion: 2027-11

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
MPT0B640	MPT0B640	There is Single Arm in this Clinical Trials.

Primary Outcome Measures

Name	Time	Method
MTD of the dose of MPT0B640	28days(+/-2days)